Get Task & Purpose in your inbox
The VA Is Eyeing Ketamine As An Emergency Treatment For Patients At High Suicide Risk
A pair of programs currently underway at a Veterans Affairs medical center in Cleveland aim to determine if a low-dose infusion of ketamine — the anesthetic that gained popularity for its street name ‘Special K’ in the 1960s and 70s — can help patients with treatment-resistant depression, and whether the drug can work as an emergency measure to help those at a high risk of suicide.
Spearheaded by Dr. Punit Vaidya, the ketamine project was one among dozens presented in late August during a Veterans Health Administration innovation event at the National Press Club in Washington. At the event, VHA employees gave ‘Shark Tank’-style presentations on projects at their clinics and fielded questions from a panel as they vied for funding to design, develop and scale their projects.
As a staff psychiatrist at the Louis Stokes Cleveland VA Medical Center in Ohio, Vaidya launched a program earlier this year to use ketamine infusion therapy as a way to expand treatment options for patients suffering from treatment-refractory depression — or in layman's terms: severe cases of depression that don't respond to antidepressants.
“Unfortunately about 30% of individuals with major depression don’t respond to medications,” Vaidya told T&P.; “So people can become desperate for things that work, because they can have a huge impact on their quality of life, and their overall functioning.”
The ketamine infusion, administered intravenously over the course of six sessions in the span of three weeks is “off-label,” meaning it’s approved by the Food and Drug Administration as an anesthetic, but not specifically designed for use in cases of treatment-resistant depression. According to Vaidya, a “handful” of veteran patients with treatment-resistant depression have participated in the project.
The effects of the ketamine infusion can often be seen within a day, if not hours, Vaidya explained.
“If you look at their depression ratings and suicidal ratings given right before treatment and even four hours later you can see a significant reduction and I think that’s really quite remarkable,” Vaidya said.
“It’s quite rapid when you compare it to a traditional medication that is offered for depression, and when it comes to suicidality there’s no other medication that’s been demonstrated to have a rapid effect,” he added.
And that’s where the second project comes in: administering the low-dose ketamine infusion to patients in the psychiatric emergency room facing a high risk of suicide.
“These would be individuals who actually came to the ER with acute suicidal ideation — they’re in imminent danger of harming themselves,” Vaidya said. “This is a more vulnerable population. High risk. I can’t think of a higher risk population than a veteran that’s in imminent danger of killing themselves.”
Still in its nascent stage, the second project will test if ketamine can work as a short term emergency measure; a stopgap to stabilize a patient, and pull them out of the “depths of the depression or suicidal thinking and bridge them into another form of treatment,” Vaidya said.
While the possibilities are intriguing, so far no ER patients have been recruited, and the ketamine isn’t a miracle cure by any means, nor will it replace long-standing treatment methods for depression or those at suicide risk. “It’s not ‘you get this and you’re done,'” Vaidya explained.
In both cases — using ketamine for those with treatment-resistant depression, and as an emergency measure — Vaidya advises cautious optimism:
“These sorts of treatments, with all the excitement, you still have to have some critical thinking, and a critical approach toward using this medication, to inform patients about these unknowns.”
New London — Retired four-star general John Kelly said that as President Donald Trump's chief of staff, he pushed back against the proposal to deploy U.S. troops to the southern border, arguing at the time that active-duty U.S. military personnel typically don't deploy or operate domestically.
"We don't like it," Kelly said in remarks at the Coast Guard Academy on Thursday night. "We see that as someone else's job meaning law enforcement."
These 'kamikaze' drones are believed to be the culprits of the attacks on 2 Saudi oil fields. Here's what we know about them
Editor's Note: This article originally appeared on Business Insider.
Yemen's Houthi rebel group, part of a regional network of militants backed by Iran, claims to be behind the drone strikes on two Saudi oil facilities that have the potential to disrupt global oil supplies.
A report from the United Nations Security Council published in January suggests that Houthi forces have obtained more powerful drone weaponry than what was previously available to them, and that the newer drones have the capability to travel greater distances and inflict more harm.
The U.S. Air Force has selected two companies to make an extreme cold-weather boot for pilots as part of a long-term effort to better protect aviators from frostbite in emergencies.
In August the service awarded a contract worth up to $4.75 million to be split between Propel LLC and the Belleville Boot Company for boots designed keep pilots' feet warm in temperatures as low as -20 Fahrenheit without the bulk of existing extreme cold weather boots, according to Debra McLean, acquisition program manager for Clothing & Textiles Domain at Air Force Life Cycle Management Command's Agile Combat Support/Human Systems Division.
DUBAI (Reuters) - Iran rejected accusations by the United States that it was behind attacks on Saudi oil plants that risk disrupting world energy supplies and warned on Sunday that U.S. bases and aircraft carriers in the region were in range of its missiles.
Yemen's Houthi group claimed responsibility for Saturday's attacks that knocked out more than half of Saudi oil output or more than 5% of global supply, but U.S. Secretary of State Mike Pompeo said the assault was the work of Iran, a Houthi ally.
Nearly a decade after he allegedly murdered an unarmed Afghan civilian during a 2010 deployment, the case of Army Maj. Matthew Golsteyn is finally going to trial.